   - Fewer biotech companies held IPOs last year
Thirteen biotechnology companies went public in 2011, compared with 16 the year before, and 20 biopharma companies that went public since 2010 are trading below their IPO price. Companies with promising products in late-stage trials or already on the market command higher share prices, says Mike Carusi, general partner with Advanced Technology Ventures. "Because of [market] volatility, the public market buyers are reluctant to jump into companies that are pre-revenue, that are not well-established, and as a result if they are going to jump in, they demand a valuation discount," he said. Genetic Engineering & Biotechnology News (12/30)        | Your job as an Exchange administrator isn't easy. You have to respond to lost messages, handle email discovery requirements, and keep everything up and running. Is there an easy way to manage your Exchange environment — and do it under budget? Learn about the challenges faced by three real organizations, and how using the right solution brought them peace of mind. |
 - Regeneron and Genentech reach partial deal for AMD drug
Genentech has reached a partial agreement with Regeneron Pharmaceuticals regarding Eylea, the latter's recently approved drug for age-related macular degeneration. Regeneron secured a nonexclusive license to some the patents that had been the subject of a lawsuit. Genentech will receive at least $60 million from Regeneron when U.S. sales of Eylea surpass $400 million along with royalties for sales above that amount. The deal is effective through May 7, 2016. The Wall Street Journal/Dow Jones Newswires (1/3) - Cellular treatment reverses aging in mice
Researchers at the University of Pittsburgh Medical Center found that injecting stem cell-like cells in mice appeared to reverse the effects of progeria, a rapid-aging condition. With the treatment, mice lived three times longer, became healthier and had better muscle strength and improved brain blood flow. The cells were taken from the muscles of younger mice. The study was published in the journal Nature Communications. ABC News (1/3)  | PAT in Green Chemistry and Green Engineering
This webinar shows how process analytical technologies and synthesis workstations in chemical reaction and crystallization design meet Green Chemistry and Engineering principles — minimizing waste, improving reaction output and decreasing by-product formation. Register for the webinar. |
 - Aveo stock lower despite positive trial data
Aveo Pharmaceuticals' study data showed investigational kidney cancer drug tivozanib was more effective than an existing drug. A late-stage trial involving patients with advanced renal cell carcinoma showed that tivozanib provided median progression-free survival of 11.9 months, compared with 9.1 months for Bayer and Onyx Pharmaceuticals' Nexavar. Investors expected 12 to 14 months from tivozanib, a JPMorgan Chase analyst said. Reuters (1/3) - Lundbeck invests in Ossianix for neurological drugs
Ossianix received a convertible promissory note from H. Lundbeck to help it develop biopharmaceutical agents for the central nervous system. Lundbeck has negotiation rights for certain medicines and technology resulting from the project. Separately, Lundbeck rolled out epilepsy treatment Onfi in the U.S. Reuters (1/3) - Apogenix gets $2.99M to develop myelodysplastic syndrome drug
The German Federal Ministry of Education and Research awarded Apogenix a grant worth $2.99 million for the clinical development of APG101, its lead fusion protein candidate, for treatment of myelodysplastic syndrome. APG101 is under Phase II development for glioblastoma multiforme. "We firmly believe that the therapeutic potential of APG101 goes far beyond the treatment of GBM and that we have a realistic chance to show proof-of-concept in a Phase II trial planned for 2013," Apogenix CEO and chief financial officer Thomas Höger said. Genetic Engineering & Biotechnology News (1/3)  | Download the latest Spotlight On… Melanoma report
This quarter’s Spotlight On… report focuses on Melanoma, which is currently experiencing an innovation breakthrough. The Spotlight On... report draws on the expert insight and strategic data from Thomson Reuters Pharma – the world's leading competitive intelligence solution. Download today. |
 | Drug Development Basic Training |  |  | | - Finox Biotech's Anjan Selz on meeting regulatory expectations
In this second of three podcasts, Anjan Selz, co-founder and CEO of Finox Biotech, a company focused on bringing biosimilars to market, discusses his interactions with the EMA and FDA and proffers that preparation and early communication are key to avoiding hurdles. Selz dispels some myths; authorities often reacted positively to negotiation and being told "no!" Selz also tackles the big question of "how similar is similar?" and talks about how going "one step further" builds credibility. Listen here. |
| Food & Agriculture | | | | | Industrial & Environmental | | | | - Range Fuels' biofuel plant sold to LanzaTech
New Zealand-based LanzaTech bought Range Fuels' sole biofuel plant as part of the U.S. ethanol producer's asset liquidation. Intellectual property was not part of the sale of the Soperton, Ga., plant that closed in January 2011 and that never began production but was designed to process wood chips into fuel. Bloomberg (1/3) | News from BIO | | | | - Are you taking full advantage of your membership?
BIO's cost-savings program, BIO Business Solutions, is helping 2,700 companies nationwide save on the cost of essential products and services. Members of BIO and 43 state and regional biotech associations are eligible to receive preferential pricing and other benefits at no additional cost beyond their membership dues. VWR International, FedEx, Office Depot and Business Wire are just a few of the industry leading providers that offer special pricing through this members-only program. Learn more or enroll here.
| SmartQuote | | | |  | When a man finds no peace within himself, it is useless to seek it elsewhere."
--Francois de La Rochefoucauld,
French writer  |
| | This SmartBrief was created for jmabs1@gmail.com
| | | Read more at SmartBrief.com | | A powerful website for SmartBrief readers including: | | | | | | | | | | Recent BIO SmartBrief Issues: - Tuesday, January 03, 2012
- Friday, December 30, 2011
- Thursday, December 29, 2011
- Wednesday, December 28, 2011
- Tuesday, December 27, 2011
| | | Lead Editor: Tom Parks
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004 | | | | | | © 1999-2012 SmartBrief, Inc.® Legal Information |
|
No comments:
Post a Comment